ArticleClinical and vaccine immunology : CVI2008
Rapid, sensitive, and specific lateral-flow immunochromatographic point-of-care device for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in serum and whole blood.
Article in Clinical and vaccine immunology : CVI, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 98 citations in OpenAlex.
- Europium nanoparticle-based lateral flow assay for rapid detection of herpes simplex virus 2-specific antibodies in serum: a preliminary evaluation.RSC advances · 2026Article
- Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis, Treatment, and Prevention.MedComm · 2026Review
- Validation of rapid point-of-care tests for herpes simplex virus-type 2 in rural Tanzania.International journal of STD & AIDS · 2025Article
- Relationship Between HSV-1 Serostatus and HSV-2 IgG Confirmation Results Using an Inhibition Assay.Sexually transmitted diseases · 2025Article
- The Interplay of Genital Herpes with Cellular Processes: A Pathogenesis and Therapeutic Perspective.Viruses · 2023Review
- Current Methods for the Detection of Antibodies of Varicella-Zoster Virus: A Review.Microorganisms · 2023Review
- Rapid diagnosis of COVID-19RSC advances · 2022Review
- Nanobiosensor-based diagnostic tools in viral infections: Special emphasis on Covid-19.Reviews in medical virology · 2022Review
- Development and Efficacy of Lateral Flow Point-of-Care Testing Devices for Rapid and Mass COVID-19 Diagnosis by the Detections of SARS-CoV-2 Antigen and Anti-SARS-CoV-2 Antibodies.Diagnostics (Basel, Switzerland) · 2021Review
- Diagnosis of Herpes Simplex Virus: Laboratory and Point-of-Care Techniques.Infectious disease reports · 2021Review
- Perspectives of characterization and bioconjugation of gold nanoparticles and their application in lateral flow immunosensing.Drug delivery and translational research · 2020Review
- Herpes simplex virus-2 infections in pregnant women from South Africa: Evaluation of the ImmunoFLOW rapid test.African journal of laboratory medicine · 2020Article
- Evaluation of a nanophosphor lateral-flow assay for self-testing for herpes simplex virus type 2 seropositivity.PloS one · 2019Article
- Development of rapid dipstick assay for food pathogens, Salmonella, by optimized parameters.Journal of food science and technology · 2019Article
- Lateral Flow Test for Visual Detection of Multiple MicroRNAs.Sensors and actuators. B, Chemical · 2018Article
- Applications of gold nanoparticles in virus detection.Theranostics · 2018Review
- Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections.Nanomedicine : nanotechnology, biology, and medicine · 2017Review
- Smart Cup: A Minimally-Instrumented, Smartphone-Based Point-of-Care Molecular Diagnostic Device.Sensors and actuators. B, Chemical · 2016Article
- Immunogenicity of varicella zoster virus glycoprotein E DNA vaccine.Experimental and therapeutic medicine · 2016Article
- Rapid Detection of Escherichia coli O157 and Shiga Toxins by Lateral Flow Immunoassays.Toxins · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes simplex virus type 2 (HSV-2) is a common human pathogen that can cause a variety of clinical manifestations in humans. In order to provide near-patient results to allow for faster counseling and treatment, a rapid point-of-care test that is accurate and simple to use is desirable. Here, we describe the development and evaluation of an HSV-2 immunoglobulin G (IgG)-specific antibody lateral-flow immunochromatographic assay (LFIA) based on colloidal gold nanoparticles. A total of 359 serum samples and 100 whole-blood samples were tested in the newly developed HSV-2 LFIA. Serum results were compared to those from the HerpeSelect HSV-2 enzyme-linked immunosorbent assay (ELISA), and whole-blood sample results were compared to those of both ELISA and HerpeSelect HSV-1 and -2 immunoblotting (IB). The sensitivity of the HSV-2 LFIA compared to that of the HerpeSelect ELISA was 100% (89/89), and the specificity was 97.3% (257/264). Cross-reactivity with HSV-1 IgG-positive serum samples was observed in 2.6% (5/196) of samples, 2.9% (1/34) for rubella virus, and 6.2% (1/16) for Epstein-Barr virus. No cross-reactivity in varicella-zoster virus or cytomegalovirus IgG-positive serum samples was observed. No interference was observed from bilirubin-, triglyceride-, albumin-, or hemoglobin-spiked samples. The concordance of the LFIA results between capillary whole blood, EDTA-treated venous whole blood, heparin-treated venous whole blood, and serum was 99% (99/100). In conclusion, the LFIA for HSV-2 IgG-specific antibodies demonstrated excellent sensitivity, specificity, and concordance for both serum and whole-blood samples compared to the sensitivity, specificity, and concordance of both HSV-2 ELISA and IB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.